How to buy KemPharm shares | $14.6

Own KemPharm shares in just a few minutes. Share price changes are updated daily.

KemPharm, Inc (KMPH) is a leading biotechnology business based in the US. On 18 June KemPharm shares plunged 9.95% to a closing position of $13.93. However, over the last 12 months, KemPharm's share price has risen by a staggering 386.67% from $3 (accounting for the 28 December 2020 split). KemPharm is listed on the NASDAQ and employs 22 staff. All prices are listed in US Dollars.

How has coronavirus impacted KemPharm's share price?

Since the stock market crash that started in February 2020, KemPharm's share price has had significant positive movement.

Its last market close was $10.24, which is 45.12% up on its pre-crash value of $5.62 (accounting for the 28 December 2020 split) and 255.56% up on the lowest point reached during the March 2020 crash when the shares fell as low as $2.88 (accounting for the 28 December 2020 split).

If you had bought $1,000 worth of KemPharm shares at the start of February 2020, those shares would have been worth $599.42 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,828.56.

KemPharm share price

Use our graph to track the performance of KMPH stocks over time.

KemPharm shares at a glance

Information last updated 2021-06-16.
Open$15.2
High$15.25
Low$14.56
Close$14.6
Previous close$15
Change $-0.4
Change % -2.6667%
Volume 415,276
Information last updated 2021-06-17.
52-week range$3.84 - $22.08
50-day moving average $10.6011
200-day moving average $10.311
Wall St. target price$19
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.729
Promoted
eToro Free Stocks

Invest in KemPharm shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Name Product Ratings Finder rating Customer rating Min. initial deposit Price per trade Frequent trader rate Platform fee Offer Link
Hargreaves Lansdown Fund and Share Account
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£1
£11.95
£5.95
£0

Capital at risk

Platform details
FREE TRADES
eToro Free Stocks
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
$200
£0
N/A
£0

Capital at risk

Platform details
FREE TRADES
Stake
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£50
US: £0
N/A
£0
Join and receive a free share worth up to £100

Capital at risk

Platform details
Degiro Share Dealing
Finder score
★★★★★
★★★★★
Expert analysis
Not yet rated
£0.01
UK: £1.75 + 0.014% (max £5)
US: €0.50 + $0.004 per share
N/A
£0

Capital at risk

Platform details
interactive investor Trading Account
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£0
£7.99 (with one free trade per month)
N/A
£9.99 per month

Capital at risk

Platform details
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy KemPharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

KemPharm price performance over time

Historical closes compared with the last close of $14.6

1 month (2021-05-20) 46.15%
3 months (2021-03-19) 31.29%
6 months (2020-12-18) -22.01%
1 year (2020-06-19) 236.59%
2 years (2019-06-20) -48.45%
3 years (2018-06-20) -85.96%
5 years (2016-06-20) -78.58%

Is KemPharm under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

EBITDA

KemPharm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.4 million.

The EBITDA is a measure of a KemPharm's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.

  • Citius Pharmaceuticals (CTXR.US): USD$-15601637
  • Acorda Therapeutics (ACOR.US): USD$-16363000

Financials

Revenue TTM $23.3 million
Operating margin TTM 21.98%
Gross profit TTM $12 million
Return on assets TTM 6.45%
Return on equity TTM -222.16%
Profit margin -74.21%
Book value $2.958
Market capitalisation $441 million

TTM: trailing 12 months

How to short and sell KemPharm shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "KMPH.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.5 million KemPharm shares held short by investors – that's known as the "short interest". This figure is 3.9% up from 3.4 million last month.

There are a few different ways that this level of interest in shorting KemPharm shares can be evaluated.

Short interest ratio (SIR)

KemPharm's "short interest ratio" (SIR) is the quantity of KemPharm shares currently shorted divided by the average quantity of KemPharm shares traded daily (recently around 580723.2405892). KemPharm's SIR currently stands at 6.11. In other words for every 100,000 KemPharm shares traded daily on the market, roughly 6110 shares are currently held short.

To gain some more context, you can compare KemPharm's short interest ratio against those of similar companies.

  • Citius Pharmaceuticals (CTXR.US): 2.5
  • Acorda Therapeutics (ACOR.US): 9.28

However KemPharm's short interest can also be evaluated against the total number of KemPharm shares, or, against the total number of tradable KemPharm shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case KemPharm's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 KemPharm shares in existence, roughly 120 shares are currently held short) or 0.1445% of the tradable shares (for every 100,000 tradable KemPharm shares, roughly 145 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against KemPharm.

Find out more about how you can short KemPharm stock.

KemPharm share dividends

We're not expecting KemPharm to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have KemPharm's shares ever split?

KemPharm's shares were split on a 1:16 basis on 28 December 2020. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.

Share price volatility

Over the last 12 months, KemPharm's shares have ranged in value from as little as $3.84 up to $22.08. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 3.3587. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put KemPharm's beta into context you can compare it against those of similar companies.

  • Citius Pharmaceuticals (CTXR.US): 1.6043
  • Acorda Therapeutics (ACOR.US): 0.6533

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site